06/28/12 - Class 514 Info Monitor Keywords Archive Organizer Account | Prev - Next
SEARCH FreshPatents: Monitor Keywords | Custom RSS
Abstract: The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1- -β-D-ribofuronamide (IB-MECA) (total daily administration of 4 mg) to subjects having moderate to severe psoriasis, was significantly more effective in treatment of the psoriatic plaques than treatment of
No comments:
Post a Comment